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ABSTRACT

Emerging rise in microbial drug resistance and the slow-growing characteristic of
some intracellular pathogens such as MAP (Mycobacterium avium subspecies
paratuberculosis) strongly urges the need for an effective approach for unconventional
drug susceptibility testing. We designed a molecular-based PCR method for the
evaluation of rifabutin (RFB) and rifampicin (RIF) resistance based on probable
determinant regions within the rpoB gene of MAP, including the 81 bp variable site
located between nucleotides 1363 and 1443. The minimum inhibitory concentration
(MIC) for RIF was also determined against 10 MAP isolates in attempt to seek
correlation with rpoB sequences. We determined that MAP strain 18 had an MIC > 30
ug/ml and > 5 ug/ml for RIF and RFB respectively, and a significant rpoB mutation
C1367T, compared to an MIC of < 1.0 ug/ml for both drugs in the wild type MAP. The
30-fold increase in the MIC was a direct result of the rpoB mutation C1367T, which
caused an amino acid change Thr456 to Ile456 in the drug’s binding site; the beta
subunit of RNA polymerase. Our in vitro induced mutation in MAP strain UCF5 resulted
in the generation of a new resistant strain (UCF5-RIF16r) that possessed T1442C rpoB
mutation and an MIC > 30 ug/ml and > 10 ug/ml for RIF and RFB respectively. The
T1442C mutation resulted in a Leu481 to Pro481 amino acid change, consequently
altering the beta subunit sequence. Sequencing the entire 3.5 kb rpoB in strains 18 and
UCF5-RIF16r revealed no additional expressed nucleotide mutation.
Of the 10 MAP strains analyzed, an additional one strain (UCF4) exhibited a
slight increase in the MIC against RIF and RFB compared to the wild-type. Nucleotide
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sequencing of the rpoB gene revealed an A2284C mutation in strain UCF4 that
occurred further downstream of the expected probable rpoB region and resulted in an
amino acid alteration Asn762 to His762. The location of this mutation outside the
binding site and its correlation with the minor increase in MIC suggests a possible
secondary interaction between the drug and the beta subunit.
We have provided three dimensional images through the utilization of PyMol
Molecular-based Graphics to display a clear comparison of the mutations observed in
the beta subunit for MAP strains 18, UCF5-RIF16r, and UCF4. We propose that these
alterations may have caused a less stable interaction between RIF and the beta
subunit, resulting in the observed increased in MIC. Furthermore, the change in amino
acid sequence did not affect the viability for our RIF resistant strains.
The data clearly illustrates that clinical and in vitro-induced MAP mutants with
rpoB mutations result in resistance to RIF and RFB. Consequently, unconventional drug
susceptibility testing such as our molecular approach will be beneficial for evaluation of
antibiotic effectiveness. This molecular approach may also serve as a model for other
drugs used for treatment of MAP infections.
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1. INTRODUCTION
1.1. Crohn’s Disease and MAP
Crohn’s disease (CD) is an inflammatory bowel disease that detrimentally affects
the epithelial lining of the digestive tract and includes symptoms such as diarrhea,
weight loss, abdominal pain, and constipation (12). The disease’s symptoms are similar
to that of the inflammatory intestinal disease found in cattle, Johne’s disease (JD) (12).
Currently a strong debate exists between CD’s potential autoimmune cause and it’s
relation to bacteria, and either concept has yet to be proven. Mycobacterium avium
subspecies. paratuberculosis, or MAP, is known to be the causative agent of Johne’s
disease and has previously been implicated in etiological studies of CD (10,11,16).
Available information regarding MAP’s role in CD has enabled ongoing studies to further
conclude the relationship between the bacteria and the human disease
(5,6,9,10,11,13,16,20,21,22,31,32,35,36,38). Evidence has shown that an insertion
sequence known as IS900 is unique to MAP, and a nested PCR reaction that amplifies
this region enables the detection of the bacteria in CD samples of blood and tissue, and
also pasteurized milk (14,31,35).
1.2. Rifabutin and Rifampicin
Rifabutin (RFB) and rifampicin (RIF) are antibiotics that belong to the rifamycin
drug family and are very similar in chemical structure. The function of these antibiotics
are to inhibit the growth of bacteria, specifically by binding to the beta subunit of RNA
polymerase through direct and indirect amino acid interactions, and preventing the
production of nascent RNA transcripts (7).
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1.3. rpoB and Rifamycin Resistance
The rpoB gene in prokaryotes encodes the beta subunit, and it is known that mutations
within this gene result in a higher level of resistance to the rifamycin antibiotics in
several bacteria (15,18,25,27,30,33). Moreover, mutations within an 81 base pair region
in rpoB spanning nucleotides 1276-1356 in Mycobacterium tuberculosis has shown to
contain the majority of alterations relating to rifamcyin resistance (34). In addition, the
V176F mutation in the beginning of rpoB has been associated with rifamycin resistance
in some strains of M. tuberculosis, however this alteration is not as prevalent as the
former (18,19).
1.4. Rifabutin and Crohn’s Disease
Previous reports have shown that RFB may potentially serve as a therapeutic
agent for the treatment of CD (17,36). As a result, more attention has been focused on
the possible use of antibiotics as an alternative remedy. However, a screening method
for RIF and RFB resistant strains of MAP has yet to be established. Therefore, as CD
therapy becomes more focused on antibiotics, it is essential that a method for
susceptibility testing be developed in order to detect and monitor MAP strains for RIF
and RFB resistance.
1.5. Fastidious MAP
Unlike other prokaryotes, MAP is very fastidious and requires unusual in vitro
growth conditions, including the addition of Mycobactin J. Additionally, MAP cultured
from CD samples has shown to lack a cell wall, and this characteristic is a major
contributing factor to the complexity of the bacteria’s primary isolation process
(23,31,32). Consequently, conventional drug susceptibility tests involving MAP are not
reliable and may result in inaccurate measurements. Therefore, the challenges faced
2

when working with this bacterium must be counteracted via alternate approaches that
could potentially result in the exposition of significant data in order to effectively treat
MAP infections.
1.6. Research Objective
In this study, we execute a molecular approach based on PCR amplification,
followed by nucleotide sequencing of regions within the rpoB gene of MAP. We attempt
to investigate and identify regions of the rpoB gene that exhibit expressed mutation and
to seek correlation between rpoB mutations in clinical MAP strains with susceptibility to
RIF and RFB.

3

2. MATERIALS AND METHODS
2.1. Bacterial Strains
Bacterial isolates investigated in this study are listed in Table 1. All clinical strains
including UCF3, UCF4, UCF5, UCF7, UCF8, M18, M185, and 61a were isolated in our
laboratory from clinical samples obtained from CD patients (37). Cow2013, and Cow5
MAP strains were recently isolated from ground beef samples from two cattle with
Johne’s disease. In addition, the MAP strains used in our study were previously isolated
from CD patients and JD cows, and were maintained in culture medium for long-term
use (Table 1).
2.2. Growth Conditions
Briefly, tissue samples were homogenized, decontaminated and then inoculated
into MGIT culture media with supplements including OADC, Mycobactin J and PANTA
as described previously (37). Prior to inoculation, each BBL MGIT 4 mL tube (Becton
Dickinson cat #245111) was supplemented with 500 µL MGIT oleic acid-albumindextrose-citrate (OADC) (Becton Dickinson cat # 245116), 100 µL antibiotic mixture
(200 U Polymyxin B. 287 mcg ampotericin B, 274 mcg nalidixic acid, 20 mcg
trimethoprim, and 20 mcg azlocillin (PANTA) (Becton Dickinson cat # 245114 ), 8 µL
Mycobactin J (0.5 mg/mL) (Allied Monitor, USA) and sucrose to a final concentration of
0.1%. Each MGIT was then inoculated with 500 µL of the homogenized sediment
suspension using 1 mL sterile syringe with a BD 18G 1½ needle. After contents were
mixed well, MGITs were incubated at 37 C in a 5% CO2. The MGIT tubes were
monitored weekly for visible turbidity or an increase in florescence quenching by
exposing the tubes to UV light at 365 nm.
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All ATCC strains were purchased from ATCC and verified in our laboratory by
biochemical and molecular testing. All cultures were subcultured in 7H10 agar
supplemented with OADC and mycobactin J. Plates were incubated at 37 oC until visible
colonies were observed. Colonies from pure culture verified by Ziel-Neelson acid fast
stain and IS900-based PCR for MAP were used to incoculate BACTEC 7H9 broth
culture supplemented with 500 uL OADC and 2.4 uM Mycobactin J. Growth index (G.I.)
was read weekly until optimum growth of desired G.I. was observed. The fresh culture
was then used for drug susceptibility testing and for molecular studies.
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Table 1 List of microorganisms used in the study.
Microorganism

Strain

Source

MAP

43544

ATCC

MAP

UCF3, Clinical Isolate

CD, Ileal

MAP

UCF4, Clinical Isolate

CD, Ileal

MAP

UCF5, Clinical Isolate

CD, Ileocolonic

MAP

UCF7, Clinical Isolate

CD, Ileocolonic

MAP

UCF8, Clinical Isolate

CD, Ileal

MAP

18, Clinical Isolate

CD, Ileal

MAP

185, Clinical Isolate

CD, mesenteric lymphnode

MAP

61a, Clinical Isolate

CD, Ileal

MAP

Cow2013

JD, ground beef

MAP

Cow5

JD, ground beef

M. avium subspecies.

25291

ATCC

M. tuberculosis

Ra25177

ATCC

M. smegmatis

607

ATCC

avium
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2.3. Minimum Inhibitory Concentration (MIC)
MIC for RIF and RFB were determined against microorganisms listed in Table 1
as follows. Starting cultures with a G.I. in the range of 500-600 were determined to be
best for inoculation. The inoculum size for each Bactec bottle used in the drug
susceptibility study was approximately 1.0 x 10^5 CFUs. Serial dilutions of RIF
concentration ranging from 0.0 to 4 ug/ml were evaluated against all microoganisms.
MAP strains resistant to RIF > 1.0 ug/ml were further tested against RIF concentrations
of 10, 20 and 30 ug/mL for MIC measurement. These MAP strains were also evaluated
against RFB at concentrations ranging from 0.0 to 10 ug/mL, excluding UCF4. MAP wild
type was included as a control in every batch of analysis. Experiments were repeated
for confirmations. Microganisms other than MAP were also evaluated for RIF
concentrations ranging from 0.0 to 10.0 ug/mL. The percentage of RIF or RFB inhibition
was used to determine the level of susceptibility for each concentration of antibiotic as
follows: % Inhibition = 1 minus (G.I of Bactec culturewithout drug minus G.I of Bactec
culture with drug G.I.)/ G.I of Bactec culturewithout drug). The MIC was also determined for
each bacterial sample, and was defined as the minimum concentration of antibiotic that
induced 90% inhibition of growth.
2.4. DNA Extraction
Extraction of genomic DNA from mycobacterial isolates was performed for
verification of the presence of the IS900 gene and for analysis of rpoB gene sequence.
For extraction of genomic DNA from Mycobacterium paratuberculosis, the boiling
method with the use of Phase-Lock Gel tubes, PLG (Eppendorf 0032005-101) gave excellent
results. The procedures for this method are summarized as follows: Before sampling,
7

incubated MGIT tubes were thoroughly vortexed. Sample of 500μL was aseptically
taken from each MGIT cultures, using a sterile disposable 1 mL syringe with a long
sterile needle BD 18G 11/2, and placed into a 1.5 mL sterile eppendorf tubes. Tubes
were centrifuged at 12,000 rpm for 10 minutes at 4 C. Supernatants were removed;
using micropipeter with aerosol barrier tips, into an autoclavable container containing 30
mL bleach. Pellets, containing mycobacterial cells, were re-suspended in 100 μL sterile
TE buffer (10 mM Tris and 1 mM EDTA, pH 8.0 HCl). The tubes were incubated in a
dry heat bath at 100 C for 30 minutes, thereafter placed on ice for 15 minutes.
Immediately prior to use, Phase-Lock Gel tubes, PLG, 2-mL light (Eppendorf cat
# 0032 005 101) were pelleted in a microcentrifuge at 12,000 rpm for 20 seconds at 4
C.. The tubes containing DNA were centrifuged at 12,000 rpm for 10 minutes at 4 C.
Supernatants were transferred into the Phase Lock Gel tubes using a micro
micropipette with sterile aerosol-barrier tips. Then, 200 µL of phenol / chloroform / iso
amayl alcohol (Acros Organics, cat # 327115000) was added to each PLG tube,
thoroughly mixed with the aqueous sample to form a transiently homogeneous
suspension.. The PLG tubes were then centrifuged at 12,000 rpm for 5 minutes at 4 C.
The gel of PLG formed a barrier between the aqueous and organic phases. The
aqueous upper phase containing DNA was carefully transferred to a fresh 1.5 mL
eppendorf sterile tube using sterile aerosol-barrier tips. To precipitate extracted DNA,
400 µL of 100% ethanol cooled to -20 C was added to each tube, mixed well, then
tubes were incubated at –20 C overnight. Tubes were centrifuged at 14,000 rpm for 20
minutes at 4 C. Supernatants were removed and DNA pellets were washed with 400
μL of 80% ethanol. Tubes were re-centrifuged at 14,000 rpm for 20 minutes at 4 C.

8

Supernatants were removed and DNA pellets were dried in a speed vacuum for 10
minute at room temperature. Finally, 50 µL of sterile millipore water was added to each
dried DNA pellet and allowed to re-dissolve at 4 C overnight.
2.5. Nested PCR
Nested PCR for IS900 amplification was performed using the primers p90/91 and
AV1/AV2 (Table 2) as described previously (31). The amplification product size was
determined on 2% agarose gel. Appropriate negative controls for PCR consisted of
sterile TE buffer or sterile water in place of the DNA template were used in parallel with
each round of PCR preparation. Positive MAP DNA from strain ATCC 43015 was
prepared independently and added to PCR tubes at a different facility using separate
supplies.
2.6. rpoB PCR
Unlike the nested IS900-based PCR assay, only one round of PCR assays were
developed for amplification of two different regions of the rpoB gene. Therefore, one
PCR reaction contained the UCF1/UCF2 primers for an amplification of 448 bp where
as the second PCR reaction contained the Knight1/Knight 2 primers for an amplification
of 587 bp. For polymerase chain reaction, the following reagents were added in
respective order in a 500-μL sterile PCR tube: 12.30 µL of Millipore sterile, filtered and
autoclaved water, 5.00 µL of 10x Platinum Taq polymerase buffer with MgCl2 (Invitrogen),
6.00 µL 25mM Magnesium solution

(Invitrogen),

8.50 µL of 3M Betaine (ICN 101003), 1.00 µL

of 10 mM each PCR Nucleotide Mix dNTP(Fisher Bp2565-2), 1.00 µL of either forward primer
UCF1 (5’TCGATGTCGCTGTCTTTCTC) or Knight1 (5’ACCACTTCGGCAACCGCCGG)
at a concentration of 0.125 μg/μL, 1.00 µL of either reverse primer UCF2 (5’
GCTCGGTGATCTGCTCGTTG) or Knight2 (5’ACTCGACCTCGCCCGCCTTG) at a
9

concentration of 0.125 μg/μL, 0.20 µL of Platinum Taq DNA Polymerase

(Invitrogen),

and

15.00 µL of extracted DNA (Template) 0.3 – 3.0 ng/µL, making a total of 50.00 µL per
0.5 µL PCR tube. Table 2 lists the nucleotide sequence for all primers used in this
study.
Additional PCR was performed for MAP strains UCF4, M18, and UCF5-RIF16r
using the same protocol as previously described. Table 4 displays information regarding
additional rpoB primers and the corresponding regions that each primer set amplifies.
2.7. PCR Purification
Each rpoB PCR product was purified from agarose using the Purelink TM Quick
Gel Extraction Kit following the procedure as described by the manufacturer
(InvitrogenTM). Purified DNA was then quantitated and subjected to nucleotide
sequencing.
2.8. Nucleotide Sequencing
Sequencing was performed using the GenomeLabTM DTCS – Quick Start Kit
following the procedure as described by the manufacturer (Beckman Coulter®). Each
sequencing reaction contained the following reagents their corresponding range of
volumes: 0 – 9.5 ul dionized H2O, 0.5 – 10 ul DNA (PCR) template, 2.0 ul primer
(forward or reverse), and 8 ul DTCS Quick Start Master Mix totaling 20 ul. The thermal
cycling protocol consisted of 30 cycles using the following times and temperatures:
96oC for 20 seconds, 50oC for 20 seconds, and 60oC for 4 minutes. Sequenced DNA
was then precipitated in individual tubes using the following protocol: a) Prepare a
labeled, sterile 0.5 ml microfuge tube for each sample, b) Prepare fresh Stop
Solution/Glycogen mixture as follows (per sequencing reaction): 2 ul of 3M Sodium
Acetate (pH5.2), 2 uL of 100 mM Na2-EDTA (pH 8.0) and 1 ul of 20 mg/mL of glycogen.
10

To each of the labeled tubes, add 5 uL of the Stop Solution/Glycogen mixture, c)
Transfer the sequencing reaction to the appropriately labeled 0.5 mL microfuge tube
and mix thoroughly, d) Add 60 uL cold 95% (v/v) ethanol/dH2O from -20oC freezer and
mix thoroughly. Immediately centrifuge at 14,000 rpm at 4oC for 15 minutes. Carefully
remove the supernatant with a micropipette (the pellet should be visible), e) Rinse the
pellet 2 times with 200 ul 70% (v/v) ethanol/dH2O from -20oC freezer. For each rinse,
centrifuge immediately at 14,000 rpm at 4oC for a minimum of 2 minutes. After
centrifugation carefully remove all of the supernatant with a micropipette, f) Vacuum dry
for 10 minutes (or until dry), g) Resuspend the sample in 40 ul of the Sample Loading
Solution (provided with kit). Following the sequencing reaction, capillary electrophoresis
was performed using the appropriate nucleotide primers for both strands of the PCR
product at the Biomolecular Science Center DNA Sequencing Core facility at the
University of Central Florida.
2.9. BLAST
BLAST and alignment sequence analyses was performed using
www.pubmed.gov. Briefly, sequences were obtained from the ftp://name@10.169.1.31
database available through the Burnett College of Biomedical Sciences at the University
of Central Florida. Sequences were used to align and BLAST against the wildtype K-10
MAP strain available on pubmed.gov. Both forward and reverse reactions were
analyzed for mismatches and sequences were reported for each MAP isolate
accordingly.
2.10. In-Vitro Mutant
A RIF resistant MAP mutant (UCF5-RIF16r) was generated through the induction
of an rpoB mutation. This was performed by exposing a wild-type MAP strain UCF5 to
11

increasing concentrations of RIF ranging from 1 to 16 ug/ml. Initially, MAP strain UCF5
was inoculated into a BACTEC bottle containing 1 ug/ml of RIF. Following incubation,
surviving MAP cells were subcultured into a new BACTEC bottle with double RIF
concentration. The process was repeated several times until a new MAP strain (UCF5RIF16r) was generated that was able to survive in the presence of 16 ug/ml of RIF. This
new resistant strain was then tested for MIC against RIF and RFB and investigated for
possible rpoB mutations as described earlier.
2.11. PyMOL Images
Protein database (pdb) file 1Ynn was obtained from the RCSB Protein Data Bank
www.rcsb.org/pdb/home/home.do website, and docking images were provided through
the use of DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application
for MacOS X (2005). Mutagenesis was displayed through using the Mutatgenesis option
in MacPyMOL.
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3. RESULTS
3.1. IS900 Verification
Genomic DNA from all bacterial isolates was subjected to IS900-based PCR in
order to confirm the identity of the MAP strains listed in Table 1. This procedure
involved two rounds of PCR, using p90/91 primers in the first round to amplify a 400 bp
sequence (Fig 1). The use of AV1/AV2 in the second round of PCR amplified a 308 bp
sequence and provided exceptional sensitivity and enhanced specificity for the
confirmation of MAP. All 10 MAP isolates were confirmed for the presence of IS900 (Fig
2, lanes 1-11). As expected, M. avium subspecies avium, M. smegmatis and M.
tuberculosis displayed negative results for the presence of the IS900 (Fig 2, lanes 1214). Succeeding the IS900 PCR analysis, genomic DNA from each identified MAP strain
was then used as template for PCR employing rpoB primers (Table 2).

1
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800
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Figure 1 IS900-based PCR for detection of MAP using P90/P91 primers.
This first round of the nested PCR using P90/P91 primers generated a 400 bp sequence displayed
on 2% agarose gel. Lanes 1-16 correspond to the following: 1, MAP strain 43544 (positive control);
2, UCF3; 3, UCF4; 4, UCF5; 5, UCF7; 6, UCF8; 7, M18; 8, MAP185; 9, Cow2013; 10, Cow5; 11, 61a;
12, M. avium; 13, M. tuberculosis; 14, M. smegmatis, 15, TE buffer; 16, negative control.
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Figure 2 IS900-based PCR for detection of MAP using AV1/AV2 primers.
This second round of the nested PCR using AV1/AV2 primers generated a 308 bp on 2% agarose
gel. Lanes 1-8 correspond to MAP strains isolated from human tissue samples (1, MAP strain
43544 (control); 2, UCF3; 3, UCF4; 4, UCF5; 5, UCF7; 6, UCF8; 7, MAP18; and 8, MAP185;
respectively. Lanes 9 and 10 correspond MAP strains derived from cattle tissue (strains Cow2013
and Cow5, respectively). Lane 11 corresponds to a new MAP strain 61a from human tissue. Lanes
12-14 correspond to M. avium subspecies avium,, M. tuberculosis and M. smegmatis, respectively.
Lanes 15 and 16 correspond to negative control for DNA extraction and PCR, respectively. A low
mass DNA molecular weight marker was used and bp are indicated on the left of the diagram.
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Table 2 PCR primers used in this study.
Primer Type

Sequence (5’ to 3”)

and Name

Amplified Base

Amplicon

Pairs (bp)*

Length (bp)

22-421

400

77-384

308

373-820

448

1191-1777

587

IS900
P90

GTTCGGGGCCGTCGCTTAGG

P91

GAGGTCGATCGCCCACGTGA

AV1

ATGTGGTTGCTGTGTTGGATGG

AV2

CCGCCGCAATCAACTCCAG

rpoB
UCF1

TCGATGTCGCTGTCTTTCTC

UCF2

GCTCGGTGATCTGCTCGTTG

Knight1

ACCACTTCGGCAACCGCCGG

Knight2

ACTCGACCTCGCCCGCCTTG

*Numbers represent nucleotide positions within the rpoB gene of MAP.
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3.2. rpoB PCR
Amplification of rpoB sequences enabled the possibility for amplicon purification,
sequencing, and subsequently BLAST analysis. The use of primers UCF1/UCF2 and
Knight1/Knight2 enabled the amplification of two regions of the rpoB gene of MAP.
These regions overlapped similar sequences in the rpoB gene of M. tuberculosis
previously associated with rifamycin resistance. Moreover, PCR with Knight1/Knight2
primers amplified a sequence that harbored the 81 bp variable site 1363-1443, a highly
probable determinant region for rifamycin resistance in closely related bacteria. Figure
3 shows the PCR results of these two regions of the rpoB gene from each of five MAP
strain representatives.

Figure 3 Partial rpoB amplicons produced by PCR.
These five samples including the positive control were chosen to represent the results of rpoB
PCR for all MAP strains in this study. Lanes 1-6 represent PCR using primers UCF1/UCF2, and
each lane corresponds to a 448 bp amplicon and is associated with the following MAP strains: 1,
43544 (positive control); 2, UCF4; 3, UCF5; 4, MAP18; 5, MAP185; 6, negative control. Lanes 7-12
represent PCR using primers Knight1/Knight2, and each lane corresponds to a 587 base pair
amplicon and is associated with the following MAP strains: 7, 43544 (positive control); 8, UCF4; 9,
UCF5; 10, MAP18; 11, MAP185; 12, negative control. A low mass DNA marker was used and the
numbers located on both sides of the image indicate base pair lengths for two different bands
within the marker. Arrows indicate location of partial rpoB DNA fragments.
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3.3. rpoB Sequencing
Nucleotide sequencing of regions ampliied by primers UCF1/UCF2 and
Knight1/Knight2 for all MAP strains was performed using a High Fidelity Platinum

Taq

polymerase. The process was repeated and the sequence was verified with both
forward and reverse primer reactions to exclude any possible errors in the data.
Therefore, sequence data was reported as completely accurate upon the confirmation
of error-free reactions. We investigated the regions amplified by primers UCF1/UCF2
and Knight1/Knight2 in 10 MAP strains, which resulted in the detection of either identical
(wild-type) or non-identical sequences (Table 3). MAP strains consisting of the latter
were further detected for silent mutations with no effect on amino acid expression, or
mutations that differentially expressed the amino acid sequence of the beta subunit. The
location of each changed amino acid was then identified and determined to lie within the
81 bp region contained in the sequence amplified by primers Knight1/Knight2 (Fig 4).
Of the 10 MAP clinical isolates, 9 (90%) consisted of no rpoB mutation in the two
regions investigated, however, 1 (10%) MAP strain, M18, possessed two rpoB
mutations, and these included C1367T and T1375C (Fig 4). The C1367T mutation
resulted in a significant amino acid change from Thr456 to Ile456 in the beta subunit of
RNA polymerase (Fig 4, Table 3). This amino acid change was considered indicative of
RIF and RFB resistance, which later was verified through susceptibility tests. The
T1375C mutation had no affect on the beta subunit, and was therefore characterized as
silent (Fig 4, Table 3). MAP isolates were then classified based on sequence
information from both regions (Fig 5). Isolates that contained no mutations were termed
wild-type and were classified as identical compared to the K-10 sequence rpoB
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sequence. Consequently, isolates that possessed mutations were classified as nonidentical. The effect of rpoB mutations in these regions on RIF and RFB susceptibility
were investigated following sequence analysis.
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Figure 4 Sequence alignment of the 81 base pair region in the rpoB gene of MAP.
The region dispayed overlaps the 81 bp rifamycin resistant determinant region within M. tuberculosis. For MAP, this sequence is
harbored in the region amplified by primers Knight1/Knight2. Indicated base pairs and amino acids range from 1363 to 1443, and 456 to
481 respectively. All RFB and RIF resistant mutations were observed within this region. Amino acid-changing rpoB mutations are
indicated for MAP18 and UCF5-RIF16r, while other rpoB mutations were considered silent. Dots correspond to homologous bases and
specific nucleotides that were changed are underlined in the control sequence.
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rpoB
BLAST results

Identical

Not Identical

No mutations
(Wildtype)

Mutations causing
amino acid change

MAP-Ben (control)
UCF3, UCF4, UCF5, UCF7
UCF8, Cow2013, Cow5, 61a

MAP18

Figure 5 Characterization of MAP isolates.
According to rpoB sequence information regarding regions amplified by primers UCF1/UCF2 and Knight1/Knight2, one of the ten MAP
isolates contained mutations, and was therefore characterized as non-identical.
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Table 3 rpoB and susceptibility data for all microorganisms.
Microorganism

Strain

RIF
MIC
(ug/ml)

RFB
MIC
(ug/ml)a

Inhib. at 1
ug/ml of RIF
(%)b

rpoB
BLAST
result c

Amino
acid
changed

MAP

ATCC43544

< 1.0

< 1.0

91

0.71

WT

None

MAP

UCF3

< 1.0

n/a

94

2.83

WT

None

MAP

UCF4

< 2.5

n/a

79

7.07

A2284C

N762H

MAP

UCF5

< 1.0

n/a

92.5

WT

None

MAP

UCF7

< 1.0

n/a

88

5,66

WT

None

MAP

UCF8

< 1.0

n/a

90

1.41

WT

None

MAP

18

> 30

< 5.0

42

1.00

1, C1367T;
2, T1375C

1, T456I;
2, silent

MAP

Cow2013

< 1.0

n/a

95

1.41

WT

None

MAP

Cow5

< 1.0

n/a

96.5

WT

None

MAP

61a

< 1.0

n/a

90

3.54

WT

None

M. avium
subspecies.
aviume

ATCC25291

< 1.0

n/a

90

1.41

n/a

n/a

M. tuberculosise

ATCC25177

< 1.0

n/a

92

1.41

n/a

n/a

M. smegmatise

ATCC607

> 9.0

n/a

6.6

1.7

n/a

n/a

UCF5-RIF16r

Modified
UCF5

> 30

> 10

32

1.41

T1442C

L481P

0.71

0.71

a. Limited investigation involving MAP18, and UCF5-RIF16r.
b. Values are expressed as means the standard deviation (SD).
c. Wildtype (WT) indicates identical investigated rpoB sequence compared to MAP K-10 strain.
d. The amino acid change is indicated with single letter amino acid codes and the corresponding codon
number.
e. rpoB sequence was not investigated
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3.4. Susceptibility
Correlation between rpoB sequence analysis and inhibitory growth rates for RIF
was assessed for all 10 MAP strains. MAP strains were initially tested against 1 ug/ml of
RIF, the MIC for our control (Fig 6). MAP strains were then subjected to MIC tests
against the same drug (Fig 7). All strains clearly indicated a susceptible characteristic
by ceasing growth at 1ug/ml of RIF, the MIC of our wild-type control, except UCF4,
M18, and UCF5-RIF16r (UCF5-RIF16r explained in later sections). More specifically, 9
MAP strains including ATCC43544 (control), UCF3-5, UCF7-8, 61a, Cow2013, Cow5,
and two non-MAP controls including M. tuberculosis and M. avium subspecies avium
had an MIC < 1.0 ug/mL for RIF (Fig 7, Table 3). After analyzing our susceptibility
results (Fig 6, Fig 7), MAP strains displaying suspicious characteristics of RIF
resistance were then subjected to a susceptibility test against RFB (Table 3). Only MAP
strain M18 displayed growth of up to 5 ug/ml of RFB, indicating partial resistance to this
drug as well. The MIC for RIF of the remaining MAP strains 18, UCF4, and M.
smegmatis was determined as > 30, < 2.5, > 9 ug/ml respectively (Table 3). Despite the
lack of rpoB mutations, M. smegmatis is commonly characterized as a naturally RIF
resistant bacteria. Table 3 summarizes rpoB mutations and susceptibility test values for
all microorganisms analyzed in this study.
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Figure 6 Percent inhibition at 1 ug/ml of RIF for each bacterial sample.
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The y-axis represents inhibition of growth expressed as a percentage. The x-axis represents all
bacterial isolates tested. The growth rate of MAP18, UCF4, MAP185, M. smegmatis and UCF5RIF16r was not affected as compared to all other isolates.

Figure 7 Minimum Inhibitory Concentration (MIC) for each bacterial sample.
The Y-axis represents the concentration of RIF expressed in ug/ml, while the X-axis represents all
bacterial samples used for MIC testing. MAP18 and UCF5-RIF16r displayed similar MICs due to
significant rpoB mutations. The MIC for MAP185 and UCF4 were slightly above that of the control,
but not comparable to the resistant MAP strains. M. smegmatis displayed RIF resistance due to
the bacterium’s natural tendency for resistance against RIF.
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3.5. UCF5-RIF16r
In order to determine the possibility of inducing in vitro RIF resistance in MAP,
our wild-type MAP strain UCF5 was cultured in two-fold increases of RIF concentration
initially beginning at a concentration of 1ug/ml. Over an extended time period, strain
UCF5 was eventually increased to 16ug/ml, a concentration in which the strain had
developed an adaptive resistance. After determining a high level of growth at this
concentration, we then termed the newly resistant MAP strain UCF5-RIF16r. The
adapted strain and was then maintained in cultures >16.0 ug/mL RIF thereafter.
Genomic DNA was extracted and followed by IS900-nested PCR and rpoBbased PCR analysis to investigate the possibility of a newly developed rpoB mutation.
After strain UCF5-RIF16r was confirmed for the presence of IS900, and both regions of
the rpoB gene were analyzed, we detected a single nucleotide rpoB mutation T1442C in
the 81 bp variable region amplified by primers Knight1/Knight2, which caused a
differentially expressed amino acid from Leu481 to Pro481 in the beta subunit of RNA
polymerase (Fig 4, Table 3). The effect of this induced mutation on susceptibility to RIF
was then investigated through susceptibility tests involving RIF as well as RFB. MAP
strain UCF5-RIF16r was tested against RIF up to greater than 30 ug/mL and up to
greater than 10 ug/mL for RFB. We determined that the MIC for UCF5-RIF16r against
RIF and RFB was > 30 ug/mL and > 10 ug/mL, respectively (Fig 7, Table 3).

24

3.6. Blood Mixture
To show the potential for sequence analysis in the rpoB gene of MAP clinical
isolates in correspondence with RIF and RFB resistance, we contaminated Human

peripheral blood mononuclear cells (PBMNC) with 1.0 x 10^3 CFU of MAP strain 18.
Prokaryotic genomic DNA was then extracted from the blood mixture, followed by
IS900-PCR and rpoB-based PCR analysis. As expected, our developed protocol
detected MAP in the blood sample and successfully amplified both regions of the rpoB
gene of MAP (data not shown). The nucleotide sequence was then analyzed for the
possible prediction of susceptibility to RIF or RFB.
3.7. Taq Alignment
Specific amino acids are commonly known to alter upon resistance to RIF in M.
tuberculosis, a close relative of MAP. Moreover, theThermus aquaticus (Taq) beta
subunit model has previously been provided and aligned with M. tuberculosis. In order
to relate our current information with that previously shown, we aligned the variable
region in MAP with Thermus aquaticus and M. tuberculosis for comparison purposes
(Fig 8). Within the alignment (Fig 8) we provided a color coding scheme obtained from
Campbell et al. 2001 corresponding to known amino acids positions and interaction data
relevant to the RIF-Taq beta subunit complex. As displayed, colored dots indicate
positions of amino acids relative to the bound RIF molecule. Amino acid alterations that
have occurred in M. tuberculosis are also noted below their corresponding positions,
and percentages are indicated for amino acid alterations that occur at high frequency
upon RIF resistance in M. tuberculosis. Amino acid changes that occurred in MAP strain
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18 and induced MAP strain UCF5-RIF16r within this region are indicated in bold at
positionsThr456 and Leu481.
According to our alignment analysis of the MAP beta subunit relevant to the
region shown in Figure 8, Arg388 in Thermus aquaticus overlaps that of Thr456 in
MAP, and this amino is not considered to make significant interactions with bound RIF
according to Campbell et. al 2001 (Fig 8). Moreover, Leu481 in MAP overlaps Leu413 in
Taq, and this amino acid is considered to make significant Vanderwaals interactions
with RIF in its bound state, possibly contributing to a more significant interaction with the
drug. The significance of our alignment is that we may determine how the amino acid
changes observed in MAP relate to commonly known residue changes that may occur
in M. tuberculosis, and to predict positions and the significance of each amino acid
within this region of the MAP beta subunit in relation to the available Taq model.
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Figure 8 Sequence alignment of MAP with Thermus aquaticus and Mycobacterium tuberculosis.
Color Key:
Grey shaded areas indicate identical residues compared to T.a.
Yellow dots correspond to amino acids that interact directly with RIF.
Green dots correspond to distal amino acids relevant to RIF.
Purple dots indicate amino acids that alter at a high frequency upon RIF resistance, with the percentage change indicated.
T.a., Thermus aquaticus
M.p. Mycobacterium avium spp. paratuberculosis
M.t. Mycobacterium tuberculosis
Bold amino acid change indicates mutations that occurred in M.p.
Figure 8 is modified from Figure 1 of Campbell et al 2001.
*Mutation that occurred only for M.p.
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3.8. 3-D perspective
In order to obtain a photographic representation of the amino acid changes that
occurred in MAP strains M18 and UCF5-RIF16r, we utilized the only available model
available through PyMol Molecular-based Graphic program (DeLano 2005) for the
display of RIF complexed with the beta subunit. The images shown are of the Taq
model for the purpose of substituting for MAP. In order to view all PyMol images, we
obtained protein database files from the RSBC PDB databank available through the
www.rcsb.org/pdb/home/home.do website. The specific pdb file that was utilized for
visualization of Taq RIF complex model was 1YNN. Through this file, we were able to
provide Figures 9, 10, 11, and 12.

3.8.1 MAP strain 18 3-D model
The first displayed RIF complex model substitutes for MAP strain M18 (Fig 9). To
describe, the Arg388 in Thermus aquaticus overlaps Thr456 in the beta subunit of MAP
strain 18 (Fig 8). In Thermus aquaticus, this amino acid residue interacts with a nearby
E384 within an alpha helix (Fig 9) which may contribute to the surrounding structure of
the RIF pocket. As mentioned, we detected a Thr456 to Ile456 in MAP strain 18. We
have shown this overlapping alteration from Arg388 to Ile388 in Thermus aquaticus for
substitute for this change in MAP, and propose that this change may possibly reflect the
observed increase in MIC due to a modification of the nearby structural atmosphere of
the bound RIF (Fig 10). For example, if the surrounding lock structure for a key is
altered, then the key will most likely not fit. More specifically, the Arg388 to Ile388
alteration may destabilize the alpha helix structure close to the RIF molecule, and
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possibly affect the surrounding structure or pocket where RIF binds, resulting in a less
stable RIF interaction.

DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005)

Figure 9 Thermus aquaticus RIF complex model for MAP wildtype.
For Thermus aquaticus, R388 (Thr456 in MAP) is located within an alpha helix nearby the RIF
antibiotic in its bound state. R388 is indicated by the white arrow. Surrounding beta subunit is
shown as green and RIF antibiotic is shown as tan. Oxygen elements are shown as red and
nitrogen elements are shown as blue.
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005)

Figure 10 Thermus aquaticus RIF complex for resistant MAP strain 18.
The specific alteration that is shown here is Arg388 to Ile388. This alteration represents that
observed for MAP strain 18, Thr456 to Ile456. This alteration may possibly destabilize RIF
interaction by altering a nearby alpha helical structure. The alteration is shown as gray,
surrounding beta subunit is shown as green and RIF antibiotic is shown as tan. Oxygen elements
are shown as red and nitrogen elements are shown as blue.
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3.8.2 UCF5-RIF16r 3-D model
The second Taq RIF complex display substitutes for our wild-type MAP strain
UCF5, as well as the induced MAP strain UCF5-RIF16r. To describe, Leu413 in
Thermus aquaticus, which overlaps Leu481 in MAP (UCF5), interacts with Leu391 in
close proximity to RIF in its bound state, contributes to Vanderwaal interactions with
RIF, and may also contribute to the interactive stability between RIF and the beta
subunit (Fig 11). As mentioned before, we have detected that a Leu481 to Pro481
alteration occurred in MAP strain UCF5-RIF16r upon resistance to RIF, and this
alteration may also destabilize RIF interaction. An illustration of the Leu413 to Pro413
alteration in Taq is provided (Fig 12). To support our statement explaining the
interaction between Leu481 and the RIF antibiotic, we have included a Taq RIF
complex diagram provided by Campbell et. al. 2001 which shows Leu413 clearly
interacting in close proximity to bound RIF (Fig 13).

3.8.3 Proposition
In both cases involving MAP strain M18 and UCF5-RIF16r, we propose that the
amino acid alteration within this variable region causes a high level of resistance to RIF
in MAP directly or indirectly. In addition, the changes observed do not affect the viability
of for both strains. The Thermus aquaticus RNA polymerase RIF-complex provides an
excellent model for illustrative purposes, and here we employ this available model to
substitute for a visual representation of the overlapping amino acids observed in our
resistant MAP strains.
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005)

Figure 11 Thermus aquaticus RIF complex for wildtype MAP strain UCF5.
Both Leu391 and Leu413 make Vanderwaals interactions with RIF in its bound state. The white
arrow indicates Leu413. Surrounding beta subunit is shown as green and RIF antibiotic is shown
as tan. Oxygen elements are shown as red and nitrogen elements are shown as blue.
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005)

Figure 12 Thermus aquaticus RIF complex for resistant MAP strain UCF-RIF16r.
The Leu413 to Pro413 alteraction may contribute an interruption in Vanderwaals interactions
between Leu413 and the RIF antibiotic, consequently destabilizing RIF interaction. The alteration
is shown as gray, surrounding beta subunit is shown as green and RIF antibiotic is shown as tan.
Oxygen elements are shown as red and nitrogen elements are shown as blue.
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Campbell et al 2001

Figure 13 Interactions with RIF and RNA polymerase.
The Lue413 residue in T.a. overlaps that of Leu481 in MAP. This diagram clearly shows Leu413 in
Taq interacting with bound RIF through Vanderwaals inteactions, as also previously stated by
Campbell et at 2001.

34

3.9. Additional Sequencing
We attempted to sequence the entire 3.5 kb rpoB gene in order to determine the
source of the variable increase in MIC for RIF against MAP strains UCF4, and to detect
any other possible rpoB mutations leading to amino acid alterations in strains M18 and
UCF5-RIF16r. Initially, we designed additional primers (Table 4) for PCR amplification
of additional sequences outside of that amplified by primers UCF1/UCF2 and
Knight1/Knight2. Our PCR results are shown in Figures 14-18, which represent the rest
of the rpoB gene in each MAP strain mentioned. After successful PCR amplification of
these regions, nucleotide sequencing was performed.
Blast analysis against the rpoB gene of MAP strain K-10 (wild-type) revealed a
significant rpoB mutation further downstream of the region amplified by Knight1/Knight2
primers in MAP strain UCF4. Specifically, an A2284C mutation occurred within the
region amplified by primers Ex1a/Ex2a. This mutation resulted in an Asn762 to His762
amino acid change, leading to a possible explanation for the observed higher MIC for
RIF compared to our wildtype control strain 43544. Moreoever, no other significant
mutations were observed in MAP strains 18 and UCF5-RIF16r. The data clearly
indicates that a single rpoB mutation may have considerable effects on RIF
susceptibility in MAP, and that the region amplified by primers Knight1/Knight2 is highly
significant for the analysis of rpoB mutations corresponding to RIF resistance.
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Table 4 Additional rpoB PCR primers.
Primer Type

Sequence (5’ to 3”)

and Name

Amplified Base

Amplicon

Pairs (bp)*

Length (bp)

1–721

721

521-1509

989

1621-2340

720

2261-2980

720

2901-3597

697

rpoB
Efox1

ttgccggccgaaccgacaca

Fox1r

tgtcgacgtcgaactccagc

Fox1f

cggtgttcatgggtgacttc

DBR

gtagtgggacgggtgcacgtc

Ex1a

aaggtggtcgacggcgtggt

Ex2a

gatctcgtgctcctcgatgt

Ex3

acgaggacgcgatcatcct

Ex4

tcgacacgatctggttcggc

Ex5

gaacatcgacggcaatcccg

Hrox1

tccgtcgaggacctggcttaa

*Numbers represent nucleotide positions within the rpoB gene of MAP.and > 9.0 ug/mL,
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Figure 14 rpoB PCR results using Efox1/Fox1r primers.
Each lane corresponds to the following MAP strains: 1, 43544 (positive control); 2, UCF4; 3, M18;
4, UCF5-RIF16r; 5, M185;, 6, negative control.

Figure 15 rpoB PCR results using Fox1/DBR primers.
Each lane corresponds to the following MAP strains: 7, 43544 (positive control); 8, UCF4; 9, M18;
10, UCF5-RIF16r; 11, M185;, 12, negative control.
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Figure 16 rpoB PCR results using Ex1a/Ex2a primers.
Each lane corresponds to the following MAP strains: 1, 43544 (positive control); 2, UCF4; 3, M18;
4, UCF5-RIF16r; 5, M185;, 6, negative control.

Figure 17 rpoB PCR results using Ex3/Ex4 primers.
Each lane corresponds to the following MAP strains: 1, 43544 (positive control); 2, UCF4; 3, M18;
4, UCF5-RIF16r; 5, M185;, 6, negative control.
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Figure 18 rpoB PCR results using Ex5/Hrox1 primers.
Each lane corresponds to the following MAP strains: 7, 43544 (positive control); 8, UCF4; 9, M18;
10, UCF5-RIF16r; 11, M185;, 12, negative control.
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3.10. UCF4 3-D model
After obtaining the entire rpoB sequence for MAP strain UCF4, which revealed a
A2284C mutation causing a Asn762 to His762 amino acid change, we provided a third
Taq RIF complex display to illustrate the observed alteration in the beta subunit. To
explain, Glu692 in Taq overlaps Asn762 in MAP, and this amino acid lies within an
alpha helical structure somewhat distant from RIF in its bound state (Fig 19). The
Glu692 to His692 change shown in Figure 20 represents the Asn762 to His762
alteration in MAP strain UCF4. Reverting back to our lock and key example, we propose
that the surrounding RIF pocket is again modified, however our RIF susceptibility tests
for strain UCF4 indicate that the modification within the beta subunit was not as
detrimental as compared to MAP strains M18 and UCF5-RIF16r.
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005)

Figure 19 Thermus aquaticus RIF complex for wild-type MAP.
The Glu692 is indicated by the white arrow, and contributes to the slpha helical structure shown.
Glu692 in this Taq model substitutes for Asn762 in wild-type MAP. Surrounding beta subunit is
shown as green and RIF antibiotic is shown as tan. Oxygen elements are shown as red and
nitrogen elements are shown as blue.
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DeLano, W.L. MacPyMOL: A PyMOL-based Molecular Graphics Application for MacOS X (2005)

Figure 20 Thermus aquaticus RIF complex for MAP strain UCF4.
The specific alteration that is shown here is Glu692 to His692 in Taq, which substitutes for the
Asn762 to His762 change seen in MAP strain UCF4. This change may possibly explain the variable
increase in MIC against RIF for strain UCF4. The alteration is shown as gray, surrounding beta
subunit is shown as green and RIF antibiotic is shown as tan. Oxygen elements are shown as red
and nitrogen elements are shown as blue.
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3.11. Entire rpoB Sequence
After collective analysis of our rpoB PCR and sequencing results, we were able
to display the entire rpoB gene sequence for MAP strains K-10, (wild-type control
sequence), M18, UCF5-RIF16r, and UCF4,. The ability to display this information was a
direct consequence of our successful PCR and sequencing reactions involving the
primers described in Table 2 and Table 4. Figures 21, 22, 23, and 24, allow a clear
observation of the significant nucleotide positions C1367, T1442 and A2284 relative to
the rest of the rpoB gene. The 81 bp region is bolded for all complete gene sequence
figures 21,22,23, and 24 and the corresponding nucleotide mutations are indicated as
blue bold for silent, and red bold for amino acid-changing. Notice that the rpoB mutation
for MAP strain UCF4 is outside of the 81 bp variable region, and as mentioned before,
this mutation led to a less significant change in the MIC against RIF. This indicates that
the significant region for detection of RIF resistance in MAP is located within the 81 bp
bolded region shown.
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1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcaccag ccagttgtcc
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg
1441 ctgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc
2281 tccaaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc
3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc
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3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa

Figure 21 Entire rpoB gene sequence for MAP strain K-10, wild-type control
sequence (Li et al 2005).
The 81 bp variable region is bolded and located between nucleotides 1363 and 1443.
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1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcactag ccagttgtcc
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg
1441 ctgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc
2281 tccaaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc
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3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc
3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa

Figure 22 Entire rpoB gene sequence for MAP strain M18.
The C1367T and T1375C mutations are indicated bold with their corresponding colors and
increased font. Red bold circled positions correspond to mutations that caused an amino acid
alteration, and blue bold correspond to silent mutations.
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1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcaccag ccagttgtcc
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg
1441 cCgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc
2281 tccaaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc
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3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc
3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa

Figure 23 Entire rpoB sequence for induced MAP strain UCF5-RIF16r.
The T1442C mutation caused an amino acid change in this strain. Red bold circled positions
correspond to mutations that caused an amino acid alteration, and blue bold correspond to silent
mutations.
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1 ttgccggccg aaccgacaca attcgcggcg aacgcagccg gtggtcccgg ccttcgtgag
61 tcgcacgagg tgctggaagg atgcatcttg gcagatttcc gccagagcaa gacggatcgc
121 ccacaaagtt cctcaaacgg atcaagttcc ttgaacggct ccgtgcccgg agcgcccaac
181 cgagtttcct tcgccaagct gcgcgaaccg ctcgaggttc ccggcctgct ggacgtgcag
241 atcgactcct tcgagtggtt gatcggcgcg ccgcggtggc gtgaggccgc gatcgcccgc
301 ggcgacgcgg agcccaaggg cgggttggaa gaggtgctcg acgagctgtc gccgatcgag
361 gacttctcgg gctcgatgtc gctgtctttc tccgaccccc gcttcgacga ggtcaaggcg
421 ccggtcgacg agtgcaaaga caaggacatg acgtacgcgg ccccgctgtt cgtcacggcc
481 gagttcatca acaacaacac cggcgagatc aagagccaga cggtgttcat gggtgacttc
541 ccgatgatga ccgagaaggg caccttcatc atcaacggga ccgagcgcgt ggtggtcagc
601 cagctggtcc gctcgccggg cgtgtacttc gacgagacca tcgacaagtc caccgagaag
661 acgctgcaca gcgtcaaggt gatccccagc cgcggcgcct ggctggagtt cgacgtcgac
721 aagcgcgaca ccgtcggcgt gcgcatcgac cgcaagcgcc gccagccggt caccgtgctg
781 ctcaaggcgc tgggttggac caacgagcag atcaccgagc ggttcggctt ctccgagatc
841 atgatgtcga cgctggagaa ggacaacacc gccggcaccg acgaggcgct gctggacatc
901 taccgcaagc tgcgcccggg cgagccgccg accaaggagt ccgcgcagac cctgctggag
961 aacctgttct tcaaggagaa gcgctacgac ctggcccggg tgggccgcta caaggtcaac
1021 aagaagctcg gcctgcacgc cggtgagccg atcaccagct cgacgctgac cgaggaagac
1081 gtcgtcgcca ccatcgagta cctggtgcgc ctgcacgagg gtcagcccac gatgaccgtc
1141 ccgggcggca tcgaggtgcc ggtggagacc gacgacatcg accacttcgg caaccgccgg
1201 ctgcgcaccg tcggtgagct gatccagaac cagatccggg tcggcatgtc ccggatggag
1261 cgcgtcgtcc gcgagcggat gaccacccag gacgtcgagg ccatcacgcc gcagaccctg
1321 atcaacatcc gtcccgtcgt ggcggcgatc aaggagttct tcggcaccag ccagttgtcc
1381 cagttcatgg accagaacaa cccgctgtcg gggctcaccc acaagcgccg cctgtcggcg
1441 ctgggcccgg gtggtctgtc ccgggagcgg gccgggctgg aggtccgcga cgtgcacccg
1501 tcccactacg gccggatgtg cccgatcgag accccggagg gtcccaacat cggtctgatc
1561 ggctcgctgt cggtgtacgc gcgggtcaac ccgttcgggt tcatcgagac gccgtaccgc
1621 aaggtggtcg acggcgtggt caccgacgag atccactacc tgaccgccga cgaggaggac
1681 cgccacgtgg tggcgcaggc caactcgccg atcgacgaca agggccggtt cgccgaggcc
1741 cgggtgctgg tccgccgcaa ggcgggcgag gtcgagtacg tgccctcgtc cgaggtggac
1801 tacatggacg tgtcaccgcg ccagatggtg tcggtggcca ccgcgatgat cccgttcctc
1861 gagcacgacg acgccaaccg tgccctgatg ggcgccaaca tgcagcgcca ggcggttccg
1921 ctggtgcgca gcgaggcgcc gctggtgggc accggcatgg agctgcgtgc cgcgatcgac
1981 gccggcgacg tcgtcgtcgc cgagaagtcc ggggtgatcg aggaggtctc cgccgactac
2041 atcaccgtga tggccgacga cggcacccgg cacacctacc ggatgcgcaa gttcgagcgg
2101 tccaaccacg gcacctgcgc caaccagagc ccgatcgtcg acgccggcga ccgggtcgag
2161 gccggccagg tcatcgccga cggtccgtgc accgagaacg gcgagatggc gctgggcaag
2221 aacctgctcg tggcgatcat gccgtgggag ggccacaact acgaggacgc gatcatcctc
2281 tccCaccggc tggttgagga ggacgtgttg acgtccatcc acatcgagga gcacgagatc
2341 gacgcccgcg acaccaagct gggcgccgag gagatcaccc gggacatccc gaacgtctcc
2401 gacgaggtgc tggccgacct ggacgagcgc ggcatcgtgc gcatcggcgc cgaggtccgc
2461 gacggcgaca tcctggtcgg caaggtcacc ccgaaggggg agaccgagct gacgccggag
2521 gagcggctgc tgcgcgccat cttcggcgag aaggcccgcg aggtccgcga cacctcgctg
2581 aaggtgccgc acggcgagtc cggcaaggtc atcggcatcc gggtgttctc ccgcgaggac
2641 gacgacgagc tgcccgccgg ggtcaacgag ctggtccgcg tctacgtggc ccagaagcgc
2701 aagatctccg acggtgacaa gctcgccggc cggcacggca acaagggcgt catcggcaag
2761 atcctgccgc aggaggacat gccgttccta ccggacggca cgccggtgga catcatcctg
2821 aacacccacg gtgtgccgcg acggatgaac atcggccaga tcctggagac ccacctgggg
2881 tgggtggcca agtccggctg gaacatcgac ggcaatcccg agtgggcggt caacctgccc
2941 gaggagctgc ggcacgcaca gccgaaccag atcgtgtcga caccggtgtt cgacggcgcc
3001 aaggaagagg agctggccgg catgctgtcg tgcacgctgc ccaaccgcga cggcgaggtc
3061 atggtggacg gcgacggcaa ggcggtgctg ttcgacggcc ggtccgggga gccgttcccg
3121 tacccggtga ccgtcggcta catgtacatc atgaagctgc accacctggt ggacgacaag
3181 atccacgccc gctccaccgg cccgtactcg atgatcaccc agcagccgct gggcggtaag
3241 gcgcagttcg gtggccagcg cttcggtgag atggagtgct gggccatgca ggcctacggc
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3301 gcggcgtaca cgctgcagga gctgttgacc atcaagtccg acgacacggt cggccgggtc
3361 aaggtgtacg aggcgatcgt caagggcgag aacatcccgg agccgggtat ccccgagtcc
3421 ttcaaggtgt tgctcaagga gctgcagtcg ctgtgcctca acgtcgaggt gctctcctcc
3481 gacggcgcgg ccatcgagct gcgcgaaggc gaggacgagg acctggagcg ggccgcggcg
3541 aacctgggaa tcaacttgtc ccgcaacgaa tccgcgtccg tcgaggacct ggcttaa

Figure 24 Entire rpoB sequence for MAP strain UCF4.
Note the A2284C mutation and its position relative further downstream of the 81 bp variable
region. Red bold circled positions correspond to mutations that caused an amino acid alteration,
and blue bold correspond to silent mutations.
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4. DISCUSSION
4.1. Purpose
The purpose of our experiment was to characterize MAP’s potential for
developing RFB and RIF resistance, associate RFB and RIF resistance with mutations
in the rpoB gene of MAP, and provide an effective protocol for detecting resistant
mutations in MAP strains linked to CD. Bacteria such as M. avium spp. avium, E. coli,
H. pylori, S. aureus and M. kansasii have laid the foundation for RFB and RIF
resistance through mutations in the rpoB gene (15,19,25,30,33). Moreover, various
strains of the closely related M. tuberculosis have set a fine trend for rifamycin
resistance, as seen through rpoB mutations (1,2,3,4,8,19,20,27,29,41). Our goal was to
discover this trend in MAP, and develop an effective method for analyzing RFB and RIF
resistance in the bacterium through rpoB-based PCR analysis.
4.2. Rationale
The overall concept of our research was to develop a method for detecting RIF
and RFB resistance in MAP strains to effectively treat CD as well as MAP related
infections. In order to thoroughly approach our goal, we established necessary steps to
evaluate the level of susceptibility to RIF and RFB in MAP. Therefore, the most effective
approach was to perform the following: Identify all MAP isolates through the commonly
known IS900 nested PCR reaction. Then investigate rpoB sequences in regions
commonly known to develop mutations upon RIF resistance. These regions were
harbored in those amplified by UCF1/UCF2 and Knight1/Knight2 primers. These regions
overlap similar sequences in the rpoB gene of M. tuberculosis that have displayed
mutations upon rifamycin resistance, including the 81 bp region 1276-1356 within
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cluster I, as well as a region further upstream in the beginning of rpoB (18,19,34).
Consequently, our determinant regions of interest in the rpoB gene of MAP were
selected based on the available information for closely related bacteria.
Our expected results were to discover no mutations in these regions for susceptible
MAP strains. However, upon our recognition of the slight increase in MIC of MAP strain
UCF4, we performed additional sequencing to address our unexpected finding and to
determine any additional mutations in our highly resistant MAP strains M18 and UCF5RIF16r. We then discovered a possible rationale for the increase in MIC in strain UCF4
through the detection of a mutation further downstream of our expected regions,
suggesting that alternative regions of the beta subunit may influence the interactive
stability between RIF and its target.
4.3. An alternative approach
There are many limitations regarding assay performance with MAP, and these
include the bacterium’s slow growing nature. To cope with this limitation, we show an
alternative approach that may be applied to this bacterium for the analysis RFB and RIF
resistance. Provided by our example of using human PBMNC-infected with MAP, we
suggest that significant data relevant to genetic resistance to antibiotics may be
obtained without the inconvenient time constraint involved with conventional inhibitory
tests. For example, analysis of the rpoB gene of MAP will indicate the likelihood of
susceptibility to RFB and RIF. This information was validated by our in vitro
susceptibility tests for using 10 MAP isolates from various sources, which display low
MICs for MAP isolates without significant rpoB mutations, and higher MICs for MAP
isolates with significant rpoB mutations.
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4.4. Molecular analysis
Of our 10 MAP isolates, 2 (20%) showed a suspicious indication for RIF
resistance, and these were MAP strains 18 and UCF4. MAP strain 18 consisted of a
significant rpoB mutation, C1367T, which induced an amino acid change in the beta
subunit, Thr456 to Ile 456, consequently causing the observed increase in MIC. On the
other hand, MAP strain UCF4 contained an rpoB mutation further downstream of the 81
bp variable site, and this mutation caused an amino acid alteration Asn762 to His762,
resulting in only a slight increase in MIC compared to strain M18. This suggests that the
81 bp region was of upmost significance for the evaluation of highly RIF and RFB
resistant MAP strains. Moreover, the difference in the level of susceptibility suggests
that this characteristic may vary depending on the location of the amino acid alteration.
4.5. Induced resistance
Our induced in vitro resistant MAP strain, UCF5-RIF16r, was indicative of RIF
resistance after it’s observed growth in the presence of 16 ug/ml, and rpoB mutation
T1442C. The new mutation caused a differential amino acid expression Leu481 to
Pro481, and its significance was observed through the association of a higher MIC
against RFB and RIF compared to the control. This data, combined with our analysis of
MAP strain 18, showed the potential for MAP to evolve resistance to RFB and RIF in
vivo and in vitro.
4.6. Blood mixture
A separate experiment in which we applied our rpoB-based protocol on human
blood mixed with a specific quantity of MAP. This was accomplished through
contaminating normal human blood with 1 x 10^3 CFU’s of MAP strain 18, and
extracting bacterial DNA directly from the blood mixture. As a result, a sufficient amount
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of bacterial DNA was obtained for successful amplification of our regions of interest
within rpoB (data not shown). The purpose of this approach was to demonstrate the
effectiveness of our protocol on CD patient blood.
4.7. Final Comments
In conclusion, through the application of our protocol on CD patient samples, we
may assist in the determination of RFB and RIF susceptible MAP strains for the
treatment of CD. Upon the observed in vitro generation of a RFB and RIF resistant MAP
strain (UCF5-RIF16r), it is likely that this trend may occur in vivo, as supported with data
from MAP strain 18. Furthermore, as RFB is applied more towards the treatment of CD,
our protocol will be of utmost significance for the optimization of CD treatment with
related antibiotics.
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